Infinity Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference

Rhea-AI Summary

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced participation in the 32nd Annual Oppenheimer Healthcare Conference on March 16, 2022, from 2:40 PM to 3:10 PM ET. CEO Adelene Perkins will present an overview and engage in 1-on-1 meetings. The company is developing eganelisib, an innovative oral immuno-oncology therapeutic, currently in multiple clinical studies including MARIO-4, MARIO-3, MARIO-275, and MARIO-P. A replay of the presentation will be accessible for 90 days following the event.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings in the 32^nd Annual Oppenheimer Healthcare Conference taking place virtually on March 16^th, 2022.

32^nd Annual Oppenheimer Healthcare Conference (virtual)

Date: March 16^th, 2022

Time: 2:40pm – 3:10pm ET

Speaker: Adelene Perkins, Chief Executive Officer

Format: Company Presentation

Webcast Registration Link.

*a replay will be available following the presentation for 90 days

About Infinity and Eganelisib

Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic in multiple clinical studies. MARIO-4 is a frontline mTNBC randomized, double-blind, pivotal trial the Company expects to initiate by the end of 2022. MARIO-3 is the first eganelisib combination study in frontline advanced cancer patients and is evaluating eganelisib in combination with Tecentriq^® and Abraxane^® in frontline TNBC and in combination with Tecentriq and Avastin^® in frontline RCC. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo^® (nivolumab) in I/O naïve urothelial cancer. MARIO-P is a platform study to evaluate eganelisib across various solid tumor indications, which the Company expects to initiate on a rolling basis in 3Q 2022. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Tecentriq^® is a registered trademark of Genentech, Inc.
Abraxane^® is a registered trademark of Abraxis BioScience, LLC.
Opdivo^® is a registered trademark of Bristol Myers Squibb.
Avastin^® is a registered trademark of Genentech, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005069/en/

Irina Koffler

LifeSci Advisors, LLC

646-970-4681

ikoffler@lifesciadvisors.com

Source: Infinity Pharmaceuticals, Inc.

FAQ

What is the date and time of Infinity Pharmaceuticals' presentation at the Oppenheimer Healthcare Conference?

Infinity Pharmaceuticals will present on March 16, 2022, from 2:40 PM to 3:10 PM ET.

Who will be presenting for Infinity Pharmaceuticals at the Oppenheimer Healthcare Conference?

CEO Adelene Perkins will be presenting at the conference.

What is eganelisib and what is its significance for Infinity Pharmaceuticals?

Eganelisib is a first-in-class oral immuno-oncology therapeutic being developed by Infinity Pharmaceuticals.

Is there a way to access Infinity Pharmaceuticals' presentation after it concludes?

Yes, a replay of the presentation will be available for 90 days after the event.

What clinical studies is Infinity Pharmaceuticals currently conducting for eganelisib?

Infinity is conducting multiple studies including MARIO-4, MARIO-3, MARIO-275, and MARIO-P.